What side effects can Valsartan have?
Below you will find the most important information about possible known side effects of Valsartan.
These side effects do not occur, but you can. Because every person reacts differently to medication. Please also note that the type and frequency of side effects may vary depending on the drug formulation (eg tablet, syringe, ointment).
Common side effects:
Drowsiness, dizziness after relocation, headache, upper respiratory tract infection, viral infection, drop in blood pressure when sitting or getting up.
Uncommon side effects:
elevation of liver function, fatigue, rash, flushing, back pain, nausea, cough, flu-like symptoms, abdominal pain, diarrhea, pharyngitis, swelling of the skin, tissue pooling, vomiting, bronchitis, runny nose, depression , Insomnia, unconsciousness without apparent cause, heart failure, conjunctivitis, nosebleeds, arthritis.
Rare side effects:
joint pain, muscle pain, swelling of the vessels, swelling of the skin and mucous membranes, rash, hives, itching, drops in some or all groups of white blood cells, nerve pain.
Very rare side effects and isolated cases:
inflammatory skin disease with clustered blisters, bleeding, acute renal failure, renal dysfunction, kidney weakness.
Occasionally, during treatment with valsartan, a decrease in red blood pigment and hematocrit (measure of toughness of the blood) was observed. Furthermore, an increase in liver function was reported in patients with hypertension. Therefore, regular medical checks of all important blood values are necessary.
What interactions does Valsartan show?
Please note that the interactions may vary depending on the drug formulation of a drug (eg tablet, syringe, ointment).
Co-administration of other antihypertensive agents may potentiate the effects of valsartan. Regular blood pressure checks are therefore necessary. Combination with the antihypertensive drug aliskiren is not recommended as it increases the risk of side effects such as potassium deficiency, hypotension and decreased renal function. This is especially true in patients with kidney dysfunction due to diabetes.
Co-administration of potassium-sparing dehydrators, potassium supplements or other potassium concentrating agents (such as anticoagulant anticoagulants and heparin) should be carried out very carefully and only with regular potassium control by the attending physician.
An increase in blood lithium concentration and the toxicity of lithium (psychotropic drugs) has been reported with concomitant use of ACE inhibitors. However, there are no therapy experiences regarding the simultaneous use of valsartan and lithium. Nevertheless, a medical monitoring of the blood lithium concentration is recommended.